新報(bào)道的一項(xiàng)臨床試驗(yàn)提示，直接向患者的淋巴結(jié)而不是皮膚注射過(guò)敏原可以極大地加快花粉過(guò)敏癥的治療。一個(gè)為期3年,、進(jìn)行54次注射的療程是目前可以長(zhǎng)期緩解花粉過(guò)敏患者癥狀的唯一的療法。許多患者沒(méi)有堅(jiān)持做完療程，而且其他一些患者常常遇到該療法的副作用,。
Thomas Kündig及其同事如今提出了一個(gè)替代方法：直接向淋巴結(jié)注射。淋巴結(jié)里聚集了免疫系統(tǒng)細(xì)胞,。這組科學(xué)家比較了兩組人類(lèi)自愿參與者的淋巴和靜脈注射療法治療花粉過(guò)敏的效果,。第一組接受了標(biāo)準(zhǔn)療法，而第二組在8周時(shí)間里等間隔地接受了3次淋巴注射,。根據(jù)這組作者,，在實(shí)驗(yàn)階段結(jié)束的時(shí)候，兩種方法帶來(lái)的保護(hù)是類(lèi)似的,，但是淋巴注射組的不良反應(yīng)的頻率和嚴(yán)重程度均更小,。接受淋巴注射的患者也報(bào)告該療法痛苦程度更低，這組作者說(shuō),，再加上注射次數(shù)的減少,，這種方法應(yīng)該可以增加完成該療法的患者數(shù)量。（生物谷Bioon.com）
生物谷推薦原始出處：
PNAS published November 10, 2008, doi:10.1073/pnas.0803725105
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Gabriela Senti, Bettina M. Prinz Vavricka, Iris Erdmann, Mella I. Diaz, Richard Markus, Stephen J. McCormack, John J. Simard, Brunello Wüthrich, Reto Crameri, Nicole Graf, P?l Johansen, and Thomas M. Kündig
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluate safety and efficacy compared with conventional s.c. immunotherapy. In a monocentric open-label trial, 165 patients with grass pollen-induced rhinoconjunctivitis were randomized to receive either 54 s.c. injections with pollen extract over 3 years [cumulative allergen dose 4,031,540 standardized quality units (SQ-U)] or 3 intralymphatic injections over 2 months (cumulative allergen dose 3,000 SQ-U). Patients were evaluated after 4 months, 1 year, and 3 years by nasal provocation, skin prick testing, IgE measurements, and symptom scores. Three low-dose intralymphatic allergen administrations increased tolerance to nasal provocation with pollen already within 4 months (P < 0.001). Tolerance was long lasting and equivalent to that achievable after standard s.c. immunotherapy (P = 0.291 after 3 years). Intralymphatic immunotherapy ameliorated hay fever symptoms (P < 0.001), reduced skin prick test reactivity (P < 0.001), decreased specific serum IgE (P < 0.001), caused fewer adverse events than s.c. immunotherapy (P = 0.001), enhanced compliance (P < 0.001), and was less painful than venous puncture (P = 0.018). In conclusion, intralymphatic allergen administration enhanced safety and efficacy of immunotherapy and reduced treatment time from 3 years to 8 weeks.
